Ken Griffin Candel Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 60,200 shares of CADL stock, worth $270,298. This represents 0.0% of its overall portfolio holdings.
Number of Shares
60,200Holding current value
$270,298% of portfolio
0.0%Shares
4 transactions
Others Institutions Holding CADL
# of Institutions
55Shares Held
6.08MCall Options Held
82.9KPut Options Held
56K-
Northpond Ventures, LLC1.94MShares$8.69 Million41.58% of portfolio
-
Vanguard Group Inc Valley Forge, PA946KShares$4.25 Million0.0% of portfolio
-
Black Rock Inc. New York, NY823KShares$3.7 Million0.0% of portfolio
-
State Street Corp Boston, MA473KShares$2.12 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA449KShares$2.02 Million0.0% of portfolio
About Candel Therapeutics, Inc.
- Ticker CADL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,891,900
- Market Cap $130M
- Description
- Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...